# Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

> **NCT07159620** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 27 (estimated)

## Conditions studied

- Adult T-cell Leukemia/Lymphoma

## Interventions

- **DRUG:** VEN (Venetoclax)
- **DRUG:** Azacitidine (AZA)
- **DRUG:** Chidamide
- **DRUG:** vindesine
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07159620
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07159620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07159620, "Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07159620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*